PD-1 Inhibitor Combined With Azacytidine and Homoharringtonine?Cytarabine, G-CSF for Refractory or Relapsed AML
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Acute Myeloid Leukemia
- Immunotherapy
- Refractory Leukemia
- Relapsed Adult AML
- Type
- Interventional
- Phase
- Phase 3
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 85 years
- Gender
- Both males and females
Description
Treatment for Acute Myeloid Leukemia?AML? that has not responded to treatment (refractory) or has returned after treatment (relapsed) often do not work. Researchers want to see if an immunotherapy drug, combined with a less intense chemotherapy, may be able to help.
Treatment for Acute Myeloid Leukemia?AML? that has not responded to treatment (refractory) or has returned after treatment (relapsed) often do not work. Researchers want to see if an immunotherapy drug, combined with a less intense chemotherapy, may be able to help.
Tracking Information
- NCT #
- NCT04722952
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Han Yue, Ph.D The First Affiliated Hospital of Soochow University
Get Well Soon